Meet Ignyta’s Board of Directors

Our Board helps make it possible for Ignyta to lead the way in precision therapeutics and molecular diagnostics.

Jonathan E. Lim, M.D. – Chairman

Jonathan Lim co-founded Ignyta as Chairman in August 2011 and joined full-time in July 2012 as President and Chief Executive Officer. Under his leadership, the company went public in 2013. It has raised nearly $350 million from financings and corporate transactions with Teva and Lilly and is focused on building a precision medicine company aspiring to eradicate residual disease in precisely defined cancer patient populations by 2030.

From May 2003 to December 2010, Dr. Lim was President, Chief Executive Officer, and a Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO). In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout. Eclipse was successfully sold to Bionomics Ltd. (ASX:BNO) in a transaction that closed in September 2012, and Dr. Lim subsequently served as a member of the Board of Directors of Bionomics for three years, until November 2015. He is also a member of the Board of Visitors of the Moores Cancer Center at UC San Diego, a position he has held since December 2015, and an Advisory Council member of Stanford Bio-X, an initiative by Stanford University to foster interdisciplinary medical research. In February 2016, Dr. Lim joined the Board and currently serves as Chairman of Bonti, Inc., a startup developing next-generation neurotoxins for patients with unmet needs in post-surgical care and aesthetic medicine.

Dr. Lim’s prior experience also includes management consulting at McKinsey & Company, an NIH Postdoctoral Fellowship at Harvard Medical School and the Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.

He has B.S. and M.S. degrees from Stanford, an M.D. from McGill, and an M.P.H. from Harvard.

James Bristol, Ph.D.

James Bristol is a distinguished leader in the field of drug discovery and chemistry with over 32 years of experience in the industry. Under Dr. Bristol’s leadership at Pfizer during the period of 2004–2006, Worldwide Discovery Research scientists at Pfizer produced more than 130 drug candidates in 11 therapeutic areas. Dr. Bristol has over 100 publications, abstracts, and patents in drug discovery programs related to a number of therapeutic areas with a focus on mechanistic biochemistry. For nearly a decade, Dr. Bristol has served as Editor in Chief of the American Chemistry Society (ACS) publication series, Annual Reports in Medicinal Chemistry.

His other prior professional activities have included serving in elected officer positions in the ACS Division of Medicinal Chemistry (Secretary, Vice Chairman, Chairman) as well as on the Board of Trustees of the Gordon Research Conferences. He has also been a Chairman of the Gordon Conference on Medicinal Chemistry, Co-Chair of the Keystone Conference, and Adjunct Professor of Medicinal Chemistry at the University of Michigan, and he has participated in numerous invited lectureships. Dr. Bristol is a Senior Advisor to Frazier Healthcare Ventures, Chairman of the Board of Managers of Deciphera Pharmaceuticals, LLC, Chairman of the Strategic and Scientific Advisory Board for Sai Advantium Ltd., member of the Polycystic Kidney Disease Foundation Drug Discovery Advisory Group, and an advisor to a select number of promising biopharmaceutical companies.

Alex Casdin

Alex Casdin is CEO and Portfolio Manager at Reneo Capital Management L.P. From September 2012 through December 2014, Mr. Casdin was a private investor focused on the healthcare sector. Previously, Mr. Casdin was the Chief Financial Officer of Sophiris Bio, Corp., a Canadian public urology company. Prior to Sophiris Bio, Mr. Casdin served as the Vice President of Finance of Amylin Pharmaceuticals, a biopharmaceutical company that was acquired by Bristol-Myers Squibb in 2012, a position he held from October 2009 to October 2011. Prior to his position at Amylin Pharmaceuticals, Mr. Casdin founded and operated Casdin Advisors, LLC, where he served as a strategic advisor to companies in the life sciences industry. Before founding Casdin Advisors, Mr. Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund. Mr. Casdin has also held previous positions at Pequot Capital Management and Dreyfus Corporation.

Mr. Casdin currently serves on the board of directors of DiaVacs, a private clinical-stage biotechnology company focused on a treatment for type 1 diabetes, and the Conquer Cancer Foundation of the American Society of Clinical Oncology. In addition, he is a member of the advisory boards of the Hassenfeld Center for Cancer & Blood Disorders and the Social Enterprise Program of the Columbia Business School, each of which are non-profit entities. He also served on the board of directors of DUSA Pharmaceuticals, a specialty pharmaceutical company in the field of dermatology that was previously listed on the NASDAQ Stock Market and was acquired by Sun Pharmaceutical Industries Limited in December 2012, from January 2009 until December 2012.

Mr. Casdin earned his B.A. degree from Brown University and his M.B.A., Beta Gamma Sigma, from Columbia Business School.

Heiner Dreismann, Ph.D.

Heiner Dreismann is highly regarded in the healthcare industry with over 26 years of experience. He serves on the boards of several innovative public and private diagnostic companies. Dr. Dreismann completed a successful career at Roche Group from 1985 to 2006, where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development at Roche Diagnostics, and Member of Roche’s Global Diagnostic Executive Committee.

Dr. Dreismann earned a Master of Science in biology and a Doctor of Philosophy in microbiology/molecular biology from Westfaelische Wilhelms University in Muenster, Germany. He conducted his Postdoctoral studies in microbial genetics at the Centre d’Etudes Nucleaires de Saclay, France.

Dr. Dreismann is an active member of the in vitro diagnostics (IVD) industry community and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique.

James Freddo, M.D.

Dr. Freddo joined our Board of Directors in 2014. Previously, Dr. Freddo was consulting to Ignyta as Consultant Chief Medical Officer. Dr. Freddo was formerly the Executive Vice President of Clinical Development and Chief Medical Officer for Ruga Corporation, a private oncology biopharmaceutical company. Prior to that, he was the Chief Medical Officer and Senior Vice President, Drug Development and a member of the Board of Directors at Anadys Pharmaceuticals, which was acquired by Roche in 2011. Prior to joining Anadys Pharmaceuticals, Dr. Freddo served at Pfizer in La Jolla, California, holding the positions of Vice President, Clinical Site Head, and Development Site Head and, prior to that, Executive Director and leader of Oncology Clinical Development. Prior to joining Pfizer, Dr. Freddo held a variety of senior management positions at Wyeth-Ayerst Research, in the oncology, infectious diseases, and transplantation immunology therapeutic areas. He has also served as a member of the Board of Directors for InfuSystems, Inc., a public healthcare products and services company.

Dr. Freddo received an M.D. degree from the University of North Carolina, Chapel Hill; completed his residency training at University of California, San Diego; and returned to Chapel Hill for his fellowship training in gynecologic oncology.

Steve Hoerter

Mr. Hoerter has served as Chief Commercial Officer of Agios Pharmaceuticals, Inc. since February 2016 and has more than twenty years of global pharmaceutical and biotechnology experience, previously having served as executive vice president and chief commercial officer at Clovis Oncology, Inc. There, Mr. Hoerter built and led the global commercial organization that developed go-to-market strategies for two oncology therapies. Before joining Clovis in 2011, he was general manager and management center head at Roche for the Sub-Saharan Africa and Indian Ocean Region.

From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as senior director, Pipeline Development and Commercial Operations. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe and Africa.

Mr. Hoerter received a B.A. from Bucknell University, an MBA from Tilburg University, and an M.S. in management from Purdue University.